These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 22499615

  • 1. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study.
    Zhu Z, Miao W, Li Q, Dai H, Ma Q, Wang F, Yang A, Jia B, Jing X, Liu S, Shi J, Liu Z, Zhao Z, Wang F, Li F.
    J Nucl Med; 2012 May; 53(5):716-22. PubMed ID: 22499615
    [Abstract] [Full Text] [Related]

  • 2. Integrin αvβ3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2.
    Zhao D, Jin X, Li F, Liang J, Lin Y.
    J Nucl Med; 2012 Dec; 53(12):1872-7. PubMed ID: 23071350
    [Abstract] [Full Text] [Related]

  • 3. Integrin Imaging with 99mTc-3PRGD2 SPECT/CT Shows High Specificity in the Diagnosis of Lymph Node Metastasis from Non-Small Cell Lung Cancer.
    Jin X, Liang N, Wang M, Meng Y, Jia B, Shi X, Li S, Luo J, Luo Y, Cui Q, Zheng K, Liu Z, Shi J, Li F, Wang F, Zhu Z.
    Radiology; 2016 Dec; 281(3):958-966. PubMed ID: 27479638
    [Abstract] [Full Text] [Related]

  • 4. [99mTc]3PRGD2 for integrin receptor imaging of esophageal cancer: a comparative study with [18F]FDG PET/CT.
    Zheng S, Chen Z, Huang C, Chen Y, Miao W.
    Ann Nucl Med; 2019 Feb; 33(2):135-143. PubMed ID: 30392070
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of [99mTc]3PRGD2 Imaging and [18F]FDG PET/CT in Breast Cancer and Expression of Integrin αvβ3 in Breast Cancer Vascular Endothelial Cells.
    Chen Z, Fu F, Li F, Zhu Z, Yang Y, Chen X, Jia B, Zheng S, Huang C, Miao W.
    Mol Imaging Biol; 2018 Oct; 20(5):846-856. PubMed ID: 29497956
    [Abstract] [Full Text] [Related]

  • 8. 99mTc-3PRGD2 SPECT/CT Imaging for Diagnosing Lymph Node Metastasis of Primary Malignant Lung Tumors.
    Xiao L, Yu S, Xu W, Sun Y, Xin J.
    Korean J Radiol; 2023 Nov; 24(11):1142-1150. PubMed ID: 37899523
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. (99m)Tc-3PRGD2 SPECT/CT Imaging for Monitoring Early Response of EGFR-TKIs Therapy in Patients with Advanced-Stage Lung Adenocarcinoma.
    Zhang Z, Zhao X, Ding C, Wang J, Zhang J, Wang F.
    Cancer Biother Radiopharm; 2016 Sep; 31(7):238-45. PubMed ID: 27563805
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of Tc-99m-3PRGD2 Integrin Receptor Imaging in the Differential Diagnosis of Breast Lesions and Comparison With Mammography.
    Chen G, Ouyang Z, Wang F, Wu H, Jia B, Chordia MD.
    Cancer Invest; 2017 Feb 07; 35(2):108-115. PubMed ID: 28135863
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Utility of Tc-PEG4-E[PEG4-c(RGDfK)]2 in Posttherapy Surveillance of Patients with Reelevated Carcinoembryonic Antigen Levels.
    Gao R, Zhang G, Chen L, Zhu Z, Wang F, Yang A.
    Med Princ Pract; 2015 Feb 07; 24(3):244-9. PubMed ID: 25871432
    [Abstract] [Full Text] [Related]

  • 15. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692.
    Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ, Study Group.
    Acta Radiol; 2010 Feb 07; 51(1):40-6. PubMed ID: 20001475
    [Abstract] [Full Text] [Related]

  • 16. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692.
    Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, Tangerud A, Tobin D.
    J Nucl Med; 2006 Sep 07; 47(9):1434-9. PubMed ID: 16954550
    [Abstract] [Full Text] [Related]

  • 17. Assessing activation of hepatic stellate cells by (99m)Tc-3PRGD2 scintigraphy targeting integrin αvβ3: a feasibility study.
    Zhang X, Xin J, Shi Y, Xu W, Yu S, Yang Z, Liu C, Cao L, Guo Q.
    Nucl Med Biol; 2015 Mar 07; 42(3):250-5. PubMed ID: 25530210
    [Abstract] [Full Text] [Related]

  • 18. Noninvasive detection of human-induced pluripotent stem cell (hiPSC)-derived teratoma with an integrin-targeting agent (99m)Tc-3PRGD2.
    Li Y, Liu Z, Dong C, He P, Liu X, Zhu Z, Jia B, Li F, Wang F.
    Mol Imaging Biol; 2013 Feb 07; 15(1):58-67. PubMed ID: 22707047
    [Abstract] [Full Text] [Related]

  • 19. ⁹⁹mTc-3PRGD₂ SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer.
    Ji B, Chen B, Wang T, Song Y, Chen M, Ji T, Wang X, Gao S, Ma Q.
    Eur J Nucl Med Mol Imaging; 2015 Aug 07; 42(9):1362-70. PubMed ID: 25947573
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.